74
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Correlation Between Cell Size and CD38 Expression in Chronic Lymphocytic Leukaemia

, , , &
Pages 797-800 | Published online: 01 Jul 2009
 

Abstract

Both CD38 expression and increased cell size are features of B-lymphocyte activation and have been implicated as adverse prognostic factors in B-cell chronic lymphocytic leukaemia (CLL). We therefore examined the relationship between these two variables by FACS analysis in 140 consecutive CLL patients. Using the mean forward-angle light scatter (FSC) as a measure of cell size, circulating B lymphocytes were found to be significantly larger in "CD38-positive" cases (those in which the antigen was expressed in at least 20% of the malignant cells) as compared with "CD38-negative" patients (p =0.029). Furthermore, within individual cases B lymphocytes expressing CD38 were, on average, significantly larger than cells that did not express the antigen (p <0.0001). Finally, when B lymphocytes of individual "CD38-positive" cases were arbitrarily divided into large and small sub-populations using their mean FSC as a cut-off, CD38 was found to be more frequently expressed on the larger cells (p <0.0001). This strong positive correlation between CD38 expression and cell size implicates cell activation as a possible underlying determinant of both tumour-cell phenotype and clinical outcome in CLL.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.